Create Medicines received Australian ethics approval to begin a first-in-human study of CRT-402, its lead in vivo CAR T program for autoimmune diseases. The company said the Human Research Ethics Committee approval (HREC) clears the path to initiate patient dosing in the Australian clinic. CRT-402 is positioned as the next step in Create’s strategy to translate in vivo CAR T concepts into an autoimmune setting, where the therapeutic focus typically includes reducing pathogenic immune activity without long-term, generalized immunosuppression. For the field, the move signals continued momentum for in vivo CAR T platforms across geographies, with regulatory and ethics clearances determining the speed of clinical start timelines.